When administered methenolone enanthate side effects parenterally to degrade partially excreted unchanged mainly via the kidney. As with all interferons in individuals with prolonged use of the drug can cause the appearance of antibodies to interferon, which leads to a decrease in therapeutic effect.
- in acute viral hepatitis B – moderate and severe forms of jaundice in the early period before the 5th day of jaundice (at a later date the appointment of the drug is less effective, the drug is not effective in developing hepatic coma and cholestatic disease course);
- lingering in acute hepatitis B and C, chronic active hepatitis B, C and D with no signs of liver cirrhosis methenolone enanthate side effects and for symptoms of cirrhosis of the liver;
- viral (influenza, adenovirus, enterovirus, herpes, mumps-tion), viral-bacterial and mycoplasma meningoencephalitis. Use of the drug is most effective during the first 4 days of the disease;
- for viral conjunctivitis, keratoconjunctivites, keratitis, keratouveitis;
- at stage IV kidney cancer, hairy cell methenolone enanthate side effects leukemia, malignant skin lymphoma (mycosis fungoides, primary reticulosis), Kaposi’s sarcoma, basal cell and squamous skin cancers, keratoacanthoma, chronic myeloid leukemia, gisteotsitoze-X subleukemic myelosis, essential thrombocytopenia;
- in multiple sclerosis.
- acute lymphoblastic leukemia methenolone enanthate side effects in remission after induction chemotherapy (4-5 month remission);
- in juvenile respiratory papillomatosis of the larynx, starting from the day after the removal of warts.
In acute hepatitis B drug is administered at 1 million ME 2 times a day for 5-6 days and then the dose was reduced to 1 million IU per day and administered for a further 5 days. If necessary (after controlling biochemical studies of blood) treatment can be continued for 1 million ME 2 times a week for 2 weeks. Heading dose of 15-21 million ME.
Lingering in acute and chronic active hepatitis in the exclusion of delta infection and without cirrhosis methenolone enanthate side effects drug is administered at 1 million ME 2 times per week for 1-2 months. In the absence of the effect of treatment extended to 3-6 months or after 1-2 months of treatment to conduct similar 2-3 courses with an interval 1-6 months.
In acute and prolonged chronically active hepatitis C without cirrhosis drug is administered at 3 million ME 3 times a week for 6-8 months. In the absence of the effect of treatment extended to 12 months.Repeated treatment after 3-6 months.
In chronic active hepatitis D without cirrhosis drug is administered at 500 th – ME 1 million per day, 2 times a week for 1 month. Repeated treatment after 1-6 months.
In chronic active hepatitis B and D with signs of liver cirrhosis is administered at 250 -500 thousand daily ME 2 times a week for one month. When you see signs of decompensation conduct similar refresher courses at intervals of not less than two months.
When kidney cancer drug is methenolone enanthate side effects used for the ME 3 million daily for 10 days. Repeated courses of treatment (3-9 or more) is carried out at intervals of 3 weeks. Total amount of the preparation is from 120 million to 300 million ME ME or more.
When volosatokpetochnom leukemia drug is administered daily for 3-6 million ME for 2 months. After normalization of the hemogram daily dose is reduced to 1-2 million ME. Then at prescribed maintenance therapy 3 ME 2 million times a week for 6-7 weeks. The total amount of drug is ME 420-600 million or more.
In acute lymphoblastic leukemia in children after remission induction chemotherapy (4-5 months of remission) – 1 million by 1 ME once a week for 6 months and then every 1 to 2 weeks for 24 months. At the same time carry out maintenance chemotherapy.
In chronic myeloid leukemia drug methenolone enanthate side effects is administered 3 million daily ME or ME 6 million a day. Duration of treatment from 10 weeks to 6 months.
When gisteotsitoze-X drug is administered 3 million ME daily for 1 month, repeated courses with 1-2-month intervals for 1-3 years
When subleukemic myelosis and essential thrombocytopenia correction hyperthrombocytosis drug is administered 1 million ME daily or every other day for 1 to 20 days.
Malignant lymphoma and Kaposi’s sarcoma drug is administered at 3 million ME per day every day for 10 days in combination with cytostatics (prospidin, cyclophosphamide) and glucocorticosteroids. When tumor stage mycosis fungoides and retikulosarkomatoze advisable to alternate the intramuscular formulation of the 3 million ME and intralesional -by ME 2 million within 10 days.
When viral, bacterial, viral and mycoplasma meningoencephalitis drug is administered 1 million ME 2 times a day for 10 days, in combination with antiviral and antibacterial chemotherapy. The dosage and treatment regimen established individually, depending on the severity of the patient’s condition.
Patients eritrodermicheskoy stage mycosis fungoides with increasing temperature over 39 C, and in the case of aggravation of the process, the introduction of the drug should be discontinued. With insufficient therapeutic effect after 10-14 days appoint a second course of treatment. After reaching a clinical effect on maintenance therapy administered 3 million ME once a week for 6-7 weeks.
In juvenile laryngeal papillomatosis respiratory preparation administered ME 100-150 thousand per kg of body weight daily for 45-50 days, then at the same dosage three times a week for one month. The second and third courses are held at intervals of 2-6 months.
When multiple sclerosis drug appoint 1 million ME when pyramidal syndrome 3 times a day, with cerebellar syndrome – 1-2 times a day for 10 days followed by administration of 1 million ME 1 time per week for 5-6 months. The total amount of the drug is 50-60 million ME.
Individuals with high pyrogenic reaction (39 ° C and above) on administration of the drug recommended simultaneous application of indomethacin.
When basal cell and squamous cell carcinoma, keratoacanthoma drug is injected under the lesion 1 million ME 1 times a day every day for 10 days. In the case of pronounced local inflammatory reactions by administering to the lesion is carried out in 1-2 days. On completion of the course, if necessary, carry out cryotherapy.
If stromal keratitis and keratoiridoiiklitah appoint subconjunctival injection of the drug at a dose of 60 thousand ME in the volume of 0.5 ml daily or every other day depending on the severity of the process.Injection is performed under local anesthesia with 0.5% tetracaine solution. The course of treatment – from 15 to 25 injections.
For topical application to the drug vial contents with activity 1 million ME was added 4 ml of sodium chloride 0.9% for injection. In the case of storage solution you need the drug, observing the rules of aseptic and antiseptic, to transfer the contents of the vial into a sterile bottle with a cork and keep the solution in a refrigerator at 4-10 ° C for up to 12 hours.
When conjunctivitis and superficial keratitis in the conjunctiva of the affected eye is applied 2 drops of solution 6-8 times a day. With the disappearance of inflammatory phenomena number of instillations reduced to 3-4 per day. The course of treatment – 2 weeks.
INTERACTION WITH OTHER DRUGS
Interferon alpha is able to reduce the methenolone enanthate side effects activity of cytochrome P-450 and, therefore, to intervene in the metabolism of cimetidine, phenytoin, chimes, theophylline, diazepam, propranolol, warfarin, certain cytostatics. It could enhance neurotoxic, myelotoxic, or cardiotoxic effects of drugs prescribed before or simultaneously with it. Avoid concomitant administration with drugs depressing the central nervous system, immunosuppressive drugs (including corticosteroids).
It is not recommended during treatment with drinking alcohol.
For parenteral administration of the drug may be chills, fever, fatigue, headache, malaise, flu-like symptoms. These side effects are partially cropped acetaminophen / paracetamol.
The local application of the drug on the mucous membrane of the eye may be conjunctival infection, redness of eyes, isolated follicles, swelling of the conjunctiva of the lower arch.
It is also possible abnormal laboratory methenolone enanthate side effects values, manifested leukopenia, lymphopenia, thrombocytopenia, increased ALT levels, alkaline phosphatase. For early detection of these abnormalities during therapy common clinical blood tests should be repeated every 2 weeks, and biochemical every 4 weeks. Generally, these changes are usually small, asymptomatic and reversible.